Rice Hall James & Associates LLC Buys 765,701 Shares of Revance Therapeutics Inc (NASDAQ:RVNC)

Share on StockTwits

Rice Hall James & Associates LLC raised its stake in shares of Revance Therapeutics Inc (NASDAQ:RVNC) by 654.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 882,769 shares of the biopharmaceutical company’s stock after acquiring an additional 765,701 shares during the quarter. Rice Hall James & Associates LLC owned approximately 2.01% of Revance Therapeutics worth $11,450,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of RVNC. Legal & General Group Plc raised its holdings in shares of Revance Therapeutics by 21.7% in the fourth quarter. Legal & General Group Plc now owns 6,445 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 1,150 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Revance Therapeutics in the fourth quarter valued at about $274,000. Geode Capital Management LLC raised its holdings in shares of Revance Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 385,818 shares of the biopharmaceutical company’s stock valued at $7,766,000 after buying an additional 48,325 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Revance Therapeutics by 197.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 225,708 shares of the biopharmaceutical company’s stock valued at $4,543,000 after buying an additional 149,952 shares during the last quarter. Finally, Deutsche Bank AG raised its holdings in shares of Revance Therapeutics by 51.1% in the fourth quarter. Deutsche Bank AG now owns 331,820 shares of the biopharmaceutical company’s stock valued at $6,678,000 after buying an additional 112,193 shares during the last quarter. 96.72% of the stock is owned by institutional investors.

A number of research analysts recently issued reports on the company. ValuEngine raised Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. William Blair reaffirmed an “outperform” rating on shares of Revance Therapeutics in a report on Tuesday, August 6th. BidaskClub raised Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 31st. Zacks Investment Research raised Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 9th. Finally, Mizuho reaffirmed a “buy” rating and issued a $37.00 price target on shares of Revance Therapeutics in a report on Wednesday, April 24th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Revance Therapeutics has a consensus rating of “Buy” and a consensus target price of $33.09.

NASDAQ:RVNC traded down $0.68 on Thursday, hitting $10.63. 297,024 shares of the stock were exchanged, compared to its average volume of 367,947. The firm has a market capitalization of $494.36 million, a PE ratio of -2.70 and a beta of 1.00. Revance Therapeutics Inc has a 52 week low of $10.37 and a 52 week high of $27.80. The business has a 50-day moving average of $12.43. The company has a quick ratio of 5.59, a current ratio of 5.59 and a debt-to-equity ratio of 0.15.

Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.86). Revance Therapeutics had a negative return on equity of 79.28% and a negative net margin of 3,745.97%. Sell-side analysts predict that Revance Therapeutics Inc will post -3.68 EPS for the current year.

About Revance Therapeutics

Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.

Further Reading: Diversification

Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics Inc (NASDAQ:RVNC).

Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.